Published in Chem Soc Rev on February 20, 2012
Novel lead structures and activation mechanisms for CO-releasing molecules (CORMs). Br J Pharmacol (2014) 1.02
The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. Br J Pharmacol (2014) 1.01
Spontaneous CO release from Ru(II)(CO)2-protein complexes in aqueous solution, cells, and mice. Angew Chem Int Ed Engl (2014) 0.88
The elements of life and medicines. Philos Trans A Math Phys Eng Sci (2015) 0.88
Mitochondria and carbon monoxide: cytoprotection and control of cell metabolism - a role for Ca(2+) ? J Physiol (2015) 0.86
Carbon monoxide and the CNS: challenges and achievements. Br J Pharmacol (2014) 0.86
Carbon monoxide--physiology, detection and controlled release. Chem Commun (Camb) (2014) 0.85
Carbon monoxide abrogates ischemic insult to neuronal cells via the soluble guanylate cyclase-cGMP pathway. PLoS One (2013) 0.84
Different design of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative differences in biological activities in terms of toxicity and inflammation. Redox Biol (2014) 0.80
Toward Carbon Monoxide-Based Therapeutics: Critical Drug Delivery and Developability Issues. J Pharm Sci (2016) 0.80
Synthesis and Characterization of a "Turn-On" photoCORM for Trackable CO Delivery to Biological Targets. ACS Med Chem Lett (2014) 0.80
The bactericidal activity of carbon monoxide-releasing molecules against Helicobacter pylori. PLoS One (2013) 0.79
Characterization of a versatile organometallic pro-drug (CORM) for experimental CO based therapeutics. Dalton Trans (2013) 0.79
Therapeutic applications of carbon monoxide. Oxid Med Cell Longev (2013) 0.78
Carbon monoxide and mitochondria-modulation of cell metabolism, redox response and cell death. Front Physiol (2015) 0.77
Carbon monoxide-releasing molecule-3 (CORM-3; Ru(CO)3Cl(glycinate)) as a tool to study the concerted effects of carbon monoxide and nitric oxide on bacterial flavohemoglobin Hmp: applications and pitfalls. J Biol Chem (2014) 0.77
A Structurally-Tunable 3-Hydroxyflavone Motif for Visible Light-Induced Carbon Monoxide-Releasing Molecules (CORMs). ChemistryOpen (2015) 0.76
Differences in the CO photolability of cis- and trans- [RuCl2(azpy)(CO)2] complexes: Effect of metal-to-ligand back-bonding. Inorganica Chim Acta (2013) 0.75
Synthesis and structures of ruthenium di- and tricarbonyl complexes derived from 4,5-diazafluoren-9-one. Acta Crystallogr C Struct Chem (2015) 0.75
An N-Acetyl Cysteine Ruthenium Tricarbonyl Conjugate Enables Simultaneous Release of CO and Ablation of Reactive Oxygen Species. Chemistry (2015) 0.75
Synthesis and crystal structure of tri-carbonyl-chlorido-{1-[(pyridin-2-yl-methyl-idene)amino]-adamantane}rhenium(I). Acta Crystallogr E Crystallogr Commun (2016) 0.75
Synthesis and assessment of CO-release capacity of manganese carbonyl complexes derived from rigid α-diimine ligands of varied complexity. Eur J Inorg Chem (2015) 0.75
Characteristics of exogenous carbon monoxide deliveries. Med Gas Res (2016) 0.75
Aspects of Carbon Monoxide in Form of CO-Releasing Molecules Used in Cancer Treatment: More Light on the Way. Oxid Med Cell Longev (2017) 0.75
Light-responsive paper strips as CO-releasing material with a colourimetric response. Chem Sci (2017) 0.75
Delivery of Antioxidant and Anti-inflammatory Agents for Tissue Engineered Vascular Grafts. Front Pharmacol (2017) 0.75
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res (2003) 2.12
Chemical modification of proteins at cysteine: opportunities in chemistry and biology. Chem Asian J (2009) 2.10
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci (2005) 1.55
A "tag-and-modify" approach to site-selective protein modification. Acc Chem Res (2011) 1.39
Allyl sulfides are privileged substrates in aqueous cross-metathesis: application to site-selective protein modification. J Am Chem Soc (2008) 1.36
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res (2006) 1.30
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Advances in chemical protein modification. Chem Rev (2015) 1.25
Antimicrobial action of carbon monoxide-releasing compounds. Antimicrob Agents Chemother (2007) 1.15
Reactive oxygen species mediate bactericidal killing elicited by carbon monoxide-releasing molecules. J Biol Chem (2011) 1.09
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther (2003) 1.07
CORM-3 reactivity toward proteins: the crystal structure of a Ru(II) dicarbonyl-lysozyme complex. J Am Chem Soc (2011) 1.06
Cysteine-selective reactions for antibody conjugation. Angew Chem Int Ed Engl (2014) 1.04
Carbon-monoxide-releasing molecules for the delivery of therapeutic CO in vivo. Angew Chem Int Ed Engl (2014) 1.02
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.99
A novel carbon monoxide-releasing molecule fully protects mice from severe malaria. Antimicrob Agents Chemother (2011) 0.99
A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl (2014) 0.92
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res (2014) 0.90
A coordinated synthesis and conjugation strategy for the preparation of homogeneous glycoconjugate vaccine candidates. Angew Chem Int Ed Engl (2011) 0.88
Spontaneous CO release from Ru(II)(CO)2-protein complexes in aqueous solution, cells, and mice. Angew Chem Int Ed Engl (2014) 0.88
Fluoroglycoproteins: ready chemical site-selective incorporation of fluorosugars into proteins. Chem Commun (Camb) (2010) 0.85
Chemical site-selective prenylation of proteins. Mol Biosyst (2008) 0.85
Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format. Chem Commun (Camb) (2012) 0.84
Inhibition of nitric oxide-stimulated vasorelaxation by carbon monoxide-releasing molecules. Arterioscler Thromb Vasc Biol (2011) 0.83
Direct radiolabelling of proteins at cysteine using [18F]-fluorosugars. Chem Commun (Camb) (2011) 0.81
Rationally designed short polyisoprenol-linked PglB substrates for engineered polypeptide and protein N-glycosylation. J Am Chem Soc (2013) 0.80
An artificial CO-releasing metalloprotein built by histidine-selective metallation. Chem Commun (Camb) (2015) 0.79
Selenenylsulfide-linked homogeneous glycopeptides and glycoproteins: synthesis of human "hepatic Se metabolite A". Angew Chem Int Ed Engl (2011) 0.79
In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer. Expert Opin Biol Ther (2006) 0.78
Protein micro- and nano-capsules for biomedical applications. Chem Soc Rev (2013) 0.78
A contribution to the rational design of Ru(CO)3Cl2L complexes for in vivo delivery of CO. Dalton Trans (2015) 0.78
Enhancing Methotrexate Tolerance with Folate Tagged Liposomes in Arthritic Mice. J Biomed Nanotechnol (2015) 0.76
Corrigendum: A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages. Nat Commun (2017) 0.75
Collagen labelling with an azide-proline chemical reporter in live cells. Chem Commun (Camb) (2015) 0.75
Nickel-Catalyzed Azide-Alkyne Cycloaddition to Access 1,5-Disubstituted 1,2,3-Triazoles in Air and Water. J Am Chem Soc (2017) 0.75